Data from a retrospective study in a cohort of 23 men with breast cancer indicate that eribulin is a safe and effective treatment for men with this disease. All patients had at least a stable disease response, with two complete responses, after a median of six treatment cycles. Patients had a median overall survival duration of 65 months. Four patients had grade ≥3 adverse events, of which two resulted in treatment interruptions, indicating that eribulin is well tolerated.
References
Giotta, F. et al. Eribulin in male patients with breast cancer: the first report of clinical outcomes. Oncologist. http://dx.doi.org/10.1634/theoncologist.2016-0022 (2016).
Rights and permissions
About this article
Cite this article
Sidaway, P. Eribulin effective against male breast cancer. Nat Rev Clin Oncol 14, 3 (2017). https://doi.org/10.1038/nrclinonc.2016.177
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.177